• PTC Therapeutics Inc PTCT.OQ reported quarterly adjusted earnings of $10.04​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of $-1.20. The mean expectation of fifteen analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from $-1.78 to $9.60 per share.

• Revenue rose 459.7% to $1.18 billion from a year ago; analysts expected $168.25 million.

• PTC Therapeutics Inc's reported EPS for the quarter was $10.04​.

• The company reported quarterly net income of $866.56 million.

• PTC Therapeutics Inc shares had fallen by 20.2% this quarter and lost 9.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 297.5% in the last three months.​

• In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 5 "hold" and 2 "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for PTC Therapeutics Inc is $58.50

This summary was machine generated from LSEG data May 6 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)